Recent scientific advances and some initial biotech successes have spurred investors to look again at gene therapy, an approach once considered all but dead. Gene therapies seem particularly apt for ocular diseases, but the pathway to approval remains largely uncharted.
Anti-angiogenesis drugs have proved game changers in the treatment of wet age-related macular degeneration, but to stave off AMD blindness,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?